	US 12,263,139 B2
	Use of cannabidiol in the treatment of tuberous sclerosis complex
Benjamin Whalley, Cambridge (GB); William Hind, Cambridge (GB); Royston Gray, Cambridge (GB); Michael Bazelot, Cambridge (GB); Ines De Silva Serra, Reading (GB); Claire Williams, Reading (GB); and Andrew Tee, Cambridge (GB)
Assigned to JAZZ PHARMACEUTICALS RESEARCH UK LIMITED, Sittingbourne (GB)
Filed by Jazz Pharmaceuticals Research UK Limited, Kent (GB)
Filed on Jan. 30, 2023, as Appl. No. 18/161,603.
Application 18/161,603 is a continuation of application No. 16/624,106, abandoned, previously published as PCT/GB2018/051733, filed on Jun. 21, 2018.
Claims priority of application No. 1710042 (GB), filed on Jun. 23, 2017.
Prior Publication US 2023/0301934 A1, Sep. 28, 2023
Int. Cl. A61K 31/05 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/05 (2013.01) [A61P 35/00 (2018.01); A61K 45/06 (2013.01)]

22 Claims

1. A method of reducing mTOR activity in a population of Tsc2−/− cells, comprising:

administering from 5 μM to 20 μM cannabidiol (CBD) to the population of Tsc2−/− cells in vitro;

wherein the CBD reduces mTOR activity in the population of Tsc2−/− cells compared to a population of Tsc2−/− cells not administered CBD.